Results 161 to 170 of about 345,692 (191)
Some of the next articles are maybe not open access.
Reumatología Clínica (English Edition), 2010
Tumor necrosis factor (TNF) is implicated in the control of tumoral growth in addition to the systemic inflammatory response. TNF blockage produces a comprensible reservation in patients with risk factors for cancer. No clear evidence for this came out from pre-clinical or clinical trials.
openaire +2 more sources
Tumor necrosis factor (TNF) is implicated in the control of tumoral growth in addition to the systemic inflammatory response. TNF blockage produces a comprensible reservation in patients with risk factors for cancer. No clear evidence for this came out from pre-clinical or clinical trials.
openaire +2 more sources
Anti-TNFs: Originators and Biosimilars
Digestive Diseases, 2016In the last 20 years, the advent of anti-tumor necrosis factor alpha (TNFα) biologics has revolutionized the treatment of patients with inflammatory bowel disease (IBD) but the cost of biologic therapy now constitutes a large proportion of all healthcare expenditures. Patent expiration has sparked the healthcare industry's interest in the production of
openaire +2 more sources
Anti-TNF agents in Crohn’s disease
Expert Opinion on Investigational Drugs, 2000The current treatment of Crohn's disease is limited by a lack of long-term efficacy of corticosteroid therapy and the associated side effects. Biological treatment strategies aimed at neutralising immune responses, offer new opportunities for the management of chronic inflammatory disorders.
G, Van Assche, P, Rutgeerts
openaire +2 more sources
TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond
Nature Reviews Rheumatology, 2023D. Siegmund, Harald Wajant
semanticscholar +1 more source
Anti‐TNF alpha medications and neuropathy
Journal of the Peripheral Nervous System, 2015AbstractWe studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐TNF) medications‐induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a‐TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an ...
Pinelopi, Tsouni +6 more
openaire +2 more sources
Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design, 2011Rheumatoid arthritis (RA), the most common autoimmune disease, is characterized by persistent synovitis and systemic inflammation. Genetic predisposition as well as autoantibodies and environmental factors, such as smoking, are associated with an increased risk of RA. Traditionally RA has been treated with disease modifying anti-rheumatic drugs (DMARDs)
Janina, Geiler +2 more
openaire +2 more sources
2016
Tumour necrosis factor-α (TNF-α) plays a relevant role in many features of asthma pathobiology by exerting its effects on both airway inflammatory and structural cells (Fig. 7.1) [1]. This pleiotropic cytokine is produced by several cell types including Th1 lymphocytes, macrophages and mast cells and induces the recruitment of neutrophils and ...
Pelaia, Girolamo +2 more
openaire +2 more sources
Tumour necrosis factor-α (TNF-α) plays a relevant role in many features of asthma pathobiology by exerting its effects on both airway inflammatory and structural cells (Fig. 7.1) [1]. This pleiotropic cytokine is produced by several cell types including Th1 lymphocytes, macrophages and mast cells and induces the recruitment of neutrophils and ...
Pelaia, Girolamo +2 more
openaire +2 more sources
Anti - TNF Therapy for Crohns Disease
Current Pharmaceutical Design, 2003Although the cause of Crohn's disease remains unknown considerable progress has been made in recent years to unravel the pathogenesis of the inflammatory processes seen in chronic idiopathic inflammatory bowel diseases (IBD). Th-1 lymphocytes seem to orchestrate the inflammation through the production of pro-inflammatory cytokines such as IFN-gamma, IL-
openaire +2 more sources